Veru advances oral sabizabulin toward Phase 2 in daraxonrasib-resistant pancreatic cancerSep 8Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Veru's Phase 2b PLATEAU trial fully enrolled with 239 obesity patientsAug 10Quarterly updateenobosarmVeru Inc.
Sign inSign in